{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T01:24:12Z","timestamp":1790126652166,"version":"4.0.1"},"reference-count":46,"publisher":"American Society of Hematology","issue":"2","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,7,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>B-cell chronic lymphocytic leukemia (B-CLL) remains an incurable disease that requires innovative new approaches to improve therapeutic outcome. Honokiol is a natural product known to possess potent antineoplastic and antiangiogenic properties. We examined whether honokiol can overcome apoptotic resistance in primary tumor cells derived from B-CLL patients. Honokiol induced caspase-dependent cell death in all of the B-CLL cells examined and was more toxic toward B-CLL cells than to normal mononuclear cells, suggesting greater susceptibility of the malignant cells. Honokiol-induced apoptosis was characterized by the activation of caspase-3, -8, and -9 and cleavage of poly(adenosine diphosphate-ribose) polymerase (PARP). Exposure of B-CLL cells to honokiol resulted in up-regulation of Bcl2-associated protein (Bax) and down-regulation of the expression of the key survival protein myeloid-cell leukemia sequence 1 (Mcl-1), which is associated with response to treatment in B-CLL patients. In addition, B-CLL cells pretreated with interleukin-4 (IL-4), a cytokine known to support B-CLL survival, underwent apoptosis when subsequently incubated with honokiol, indicating that honokiol could also overcome the prosurvival effects of IL-4. Furthermore, honokiol enhanced cytotoxicity induced by fludarabine, cladribine, or chlorambucil. These data indicate that honokiol is a potent inducer of apoptosis in B-CLL cells and should be examined for further clinical application either as a single agent or in combination with other anticancer agents. (Blood. 2005;106:690-697)<\/jats:p>","DOI":"10.1182\/blood-2004-11-4273","type":"journal-article","created":{"date-parts":[[2005,4,1]],"date-time":"2005-04-01T01:34:49Z","timestamp":1112319289000},"page":"690-697","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":170,"title":["The natural product honokiol induces caspase-dependent apoptosis in B-cell chronic lymphocytic leukemia (B-CLL) cells"],"prefix":"10.1182","volume":"106","author":[{"given":"Traci E.","family":"Battle","sequence":"first","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and Department of Dermatology, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Arbiser","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and Department of Dermatology, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Frank","sequence":"additional","affiliation":[{"name":"From the Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA; Departments of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA; and Department of Dermatology, Emory University School of Medicine, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223391371900_REF1","unstructured":"Li TSC. Chinese and Related North American Herbs: Phytopharmacology and Therapeutic Values. Boca Raton, FL: CRC Press; 2002."},{"key":"2020021223391371900_REF2","doi-asserted-by":"crossref","unstructured":"Tsai TH, Chen C.F. Identification and determination of honokiol and magnolol from Magnolis officinalis by high-performance liquid chromatography with photodiode-array UV detection. J Chromatogr.1992;598: 143-146.","DOI":"10.1016\/0021-9673(92)85125-D"},{"key":"2020021223391371900_REF3","doi-asserted-by":"crossref","unstructured":"Teng CM, Chen CC, Ko FN, et al. Two antiplatelet agents from Magnolia officinalis. Thromb Res.1988;50: 757-765.","DOI":"10.1016\/0049-3848(88)90336-2"},{"key":"2020021223391371900_REF4","doi-asserted-by":"crossref","unstructured":"Clark AM, El-Feraly FS, Li WS. Antimicrobial activity of phenolic constituents of Magnolia grandiflora L. J Pharm Sci.1981;70: 951-952.","DOI":"10.1002\/jps.2600700833"},{"key":"2020021223391371900_REF5","doi-asserted-by":"crossref","unstructured":"Liou KT, Shen YC, Chen CF, Tsao CM, Tsai SK. Honokiol protects rat brain from focal cerebral ischemia-reperfusion injury by inhibiting neutrophil infiltration and reactive oxygen species production. Brain Res.2003;992: 159-166.","DOI":"10.1016\/j.brainres.2003.08.026"},{"key":"2020021223391371900_REF6","doi-asserted-by":"crossref","unstructured":"Watanabe K, Watanabe H, Goto Y, Yamaguchi M, Yamamoto N, Hagino K. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects. Planta Med.1983;49: 103-108.","DOI":"10.1055\/s-2007-969825"},{"key":"2020021223391371900_REF7","doi-asserted-by":"crossref","unstructured":"Hirano T, Gotoh M, Oka K. Natural flavonoids and lignans are potent cytostatic agents against human leukemic HL-60 cells. Life Sci.1994;55: 1061-1069.","DOI":"10.1016\/0024-3205(94)00641-5"},{"key":"2020021223391371900_REF8","doi-asserted-by":"crossref","unstructured":"Bai X, Cerimele F, Ushio-Fukai M, et al. Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem.2003;278: 35501-35507.","DOI":"10.1074\/jbc.M302967200"},{"key":"2020021223391371900_REF9","doi-asserted-by":"crossref","unstructured":"Hibasami H, Achiwa Y, Katsuzaki H, et al. Honokiol induces apoptosis in human lymphoid leukemia Molt 4B cells. Int J Mol Med.1998;2: 671-673.","DOI":"10.3892\/ijmm.2.6.671"},{"key":"2020021223391371900_REF10","doi-asserted-by":"crossref","unstructured":"Wang T, Chen F, Chen Z, et al. Honokiol induces apoptosis through p53-independent pathway in human colorectal cell line RKO. World J Gastroenterol.2004;10: 2205-2208.","DOI":"10.3748\/wjg.v10.i15.2205"},{"key":"2020021223391371900_REF11","doi-asserted-by":"crossref","unstructured":"Yang SE, Hsieh MT, Tsai TH, Hsu SL. Down-modulation of Bcl-XL, release of cytochrome c and sequential activation of caspases during honokiol-induced apoptosis in human squamous lung cancer CH27 cells. Biochem Pharmacol.2002;63: 1641-1651.","DOI":"10.1016\/S0006-2952(02)00894-8"},{"key":"2020021223391371900_REF12","doi-asserted-by":"crossref","unstructured":"Cerimele F, Battle T, Lynch R, et al. Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A.2005;102: 175-179.","DOI":"10.1073\/pnas.0408381102"},{"key":"2020021223391371900_REF13","doi-asserted-by":"crossref","unstructured":"Konoshima T, Kozuka M, Tokuda H, et al. Studies on inhibitors of skin tumor promotion, IX. Neolignans from Magnolia officinalis. J Nat Prod.1991;54: 816-822.","DOI":"10.1021\/np50075a010"},{"key":"2020021223391371900_REF14","doi-asserted-by":"crossref","unstructured":"Hanada M, Delia D, Aiello A, Stadtmauer E, Reed JC. bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood.1993;82: 1820-1828.","DOI":"10.1182\/blood.V82.6.1820.1820"},{"key":"2020021223391371900_REF15","doi-asserted-by":"crossref","unstructured":"Kitada S, Andersen J, Akar S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood.1998;91: 3379-3389.","DOI":"10.1182\/blood.V91.9.3379"},{"key":"2020021223391371900_REF16","doi-asserted-by":"crossref","unstructured":"Pedersen IM, Kitada S, Leoni LM, et al. Protection of CLL B cells by a follicular dendritic cell line is dependent on induction of Mcl-1. Blood.2002;100: 1795-1801.","DOI":"10.1182\/blood.V100.5.1795.h81702001795_1795_1801"},{"key":"2020021223391371900_REF17","doi-asserted-by":"crossref","unstructured":"Chu P, Deforce D, Pedersen IM, et al. Latent sensitivity to Fas-mediated apoptosis after CD40 ligation may explain activity of CD154 gene therapy in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A.2002;99: 3854-3859.","DOI":"10.1073\/pnas.022604399"},{"key":"2020021223391371900_REF18","doi-asserted-by":"crossref","unstructured":"MacFarlane M, Harper N, Snowden RT, et al. Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia. Oncogene.2002;21: 6809-6818.","DOI":"10.1038\/sj.onc.1205853"},{"key":"2020021223391371900_REF19","doi-asserted-by":"crossref","unstructured":"Francia di Celle P, Mariani S, Riera L, Stacchini A, Reato G, Foa R. Interleukin-8 induces the accumulation of B-cell chronic lymphocytic leukemia cells by prolonging survival in an autocrine fashion. Blood.1996;87: 4382-4389.","DOI":"10.1182\/blood.V87.10.4382.bloodjournal87104382"},{"key":"2020021223391371900_REF20","doi-asserted-by":"crossref","unstructured":"Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med.1992;176: 1319-1326.","DOI":"10.1084\/jem.176.5.1319"},{"key":"2020021223391371900_REF21","doi-asserted-by":"crossref","unstructured":"Ferrajoli A, Keating MJ, Manshouri T, et al. The clinical significance of tumor necrosis factor-alpha plasma level in patients having chronic lymphocytic leukemia. Blood.2002;100: 1215-1219.","DOI":"10.1182\/blood.V100.4.1215.h81602001215_1215_1219"},{"key":"2020021223391371900_REF22","doi-asserted-by":"crossref","unstructured":"Aguayo A, O'Brien S, Keating M, et al. Clinical relevance of intracellular vascular endothelial growth factor levels in B-cell chronic lymphocytic leukemia. Blood.2000;96: 768-770.","DOI":"10.1182\/blood.V96.2.768"},{"key":"2020021223391371900_REF23","doi-asserted-by":"crossref","unstructured":"Kay NE, Bone ND, Tschumper RC, et al. B-CLL cells are capable of synthesis and secretion of both pro- and anti-angiogenic molecules. Leukemia.2002;16: 911-919.","DOI":"10.1038\/sj.leu.2402467"},{"key":"2020021223391371900_REF24","doi-asserted-by":"crossref","unstructured":"Decker T, Oelsner M, Kreitman RJ, et al. Induction of caspase-dependent programmed cell death in B-cell chronic lymphocytic leukemia by anti-CD22 immunotoxins. Blood.2004;103: 2718-2726.","DOI":"10.1182\/blood-2003-04-1317"},{"key":"2020021223391371900_REF25","doi-asserted-by":"crossref","unstructured":"Luo X, Budihardjo I, Zou H, Slaughter C, Wang X. Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell.1998;94: 481-490.","DOI":"10.1016\/S0092-8674(00)81589-5"},{"key":"2020021223391371900_REF26","doi-asserted-by":"crossref","unstructured":"Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell.1998;94: 491-501.","DOI":"10.1016\/S0092-8674(00)81590-1"},{"key":"2020021223391371900_REF27","doi-asserted-by":"crossref","unstructured":"Robertson LE, Plunkett W. Apoptotic cell death in chronic lymphocytic leukemia. Leuk Lymphoma.1993;11(suppl 2): 71-74.","DOI":"10.3109\/10428199309064265"},{"key":"2020021223391371900_REF28","doi-asserted-by":"crossref","unstructured":"Saxena A, Viswanathan S, Moshynska O, Tandon P, Sankaran K, Sheridan DP. Mcl-1 and Bcl-2\/Bax ratio are associated with treatment response but not with Rai stage in B-cell chronic lymphocytic leukemia. Am J Hematol.2004;75: 22-33.","DOI":"10.1002\/ajh.10453"},{"key":"2020021223391371900_REF29","doi-asserted-by":"crossref","unstructured":"Zhan Q, Bieszczad CK, Bae I, Fornace AJ Jr, Craig RW. Induction of BCL2 family member MCL1 as an early response to DNA damage. Oncogene.1997;14: 1031-1039.","DOI":"10.1038\/sj.onc.1200927"},{"key":"2020021223391371900_REF30","doi-asserted-by":"crossref","unstructured":"Yang T, Buchan HL, Townsend KJ, Craig RW. MCL-1, a member of the BLC-2 family, is induced rapidly in response to signals for cell differentiation or death, but not to signals for cell proliferation. J Cell Physiol.1996;166: 523-536.","DOI":"10.1002\/(SICI)1097-4652(199603)166:3<523::AID-JCP7>3.0.CO;2-R"},{"key":"2020021223391371900_REF31","doi-asserted-by":"crossref","unstructured":"Marriott HM, Bingle CD, Read RC, et al. Dynamic changes in Mcl-1 expression regulate macrophage viability or commitment to apoptosis during bacterial clearance. J Clin Invest.2005;115: 359-368.","DOI":"10.1172\/JCI200521766"},{"key":"2020021223391371900_REF32","doi-asserted-by":"crossref","unstructured":"Frankfurt OS, Byrnes JJ, Villa L. Protection from apoptotic cell death by interleukin-4 is increased in previously treated chronic lymphocytic leukemia patients. Leuk Res.1997;21: 9-16.","DOI":"10.1016\/S0145-2126(96)00053-7"},{"key":"2020021223391371900_REF33","doi-asserted-by":"crossref","unstructured":"Castejon R, Vargas JA, Romero Y, Briz M, Munoz RM, Durantez A. Modulation of apoptosis by cytokines in B-cell chronic lymphocytic leukemia. Cytometry.1999;38: 224-230.","DOI":"10.1002\/(SICI)1097-0320(19991015)38:5<224::AID-CYTO4>3.0.CO;2-0"},{"key":"2020021223391371900_REF34","doi-asserted-by":"crossref","unstructured":"Mainou-Fowler T, Prentice AG. Modulation of apoptosis with cytokines in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma.1996;21: 369-377.","DOI":"10.3109\/10428199609093434"},{"key":"2020021223391371900_REF35","doi-asserted-by":"crossref","unstructured":"Byrd JC, Shinn C, Waselenko JK, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood.1998;92: 3804-3816.","DOI":"10.1182\/blood.V92.10.3804"},{"key":"2020021223391371900_REF36","doi-asserted-by":"crossref","unstructured":"Battle TE, Frank DA. STAT1 mediates differentiation of chronic lymphocytic leukemia cells in response to Bryostatin 1. Blood.2003;102: 3016-3024.","DOI":"10.1182\/blood-2002-09-2972"},{"key":"2020021223391371900_REF37","doi-asserted-by":"crossref","unstructured":"Inoue S, Snowden RT, Dyer MJ, Cohen GM. CDDO induces apoptosis via the intrinsic pathway in lymphoid cells. Leukemia.2004;18: 948-952.","DOI":"10.1038\/sj.leu.2403328"},{"key":"2020021223391371900_REF38","doi-asserted-by":"crossref","unstructured":"Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood.2004;104: 788-794.","DOI":"10.1182\/blood-2003-08-2763"},{"key":"2020021223391371900_REF39","doi-asserted-by":"crossref","unstructured":"Byrd JC, Lucas DM, Mone AP, Kitner JB, Drabick JJ, Grever MR. KRN5500: a novel therapeutic agent with in vitro activity against human B-cell chronic lymphocytic leukemia cells mediates cytotoxicity via the intrinsic pathway of apoptosis. Blood.2003;101: 4547-4550.","DOI":"10.1182\/blood-2002-08-2623"},{"key":"2020021223391371900_REF40","doi-asserted-by":"crossref","unstructured":"Battle TE, Castro-Malaspina H, Gribben JG, Frank DA. Sustained complete remission of CLL associated with the use of a Chinese herbal extract: case report and mechanistic analysis. Leuk Res.2003;27: 859-863.","DOI":"10.1016\/S0145-2126(03)00009-2"},{"key":"2020021223391371900_REF41","doi-asserted-by":"crossref","unstructured":"Pepper C, Hoy T, Bentley DP. Bcl-2\/Bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro apoptosis and clinical resistance. Br J Cancer.1997;76: 935-938.","DOI":"10.1038\/bjc.1997.487"},{"key":"2020021223391371900_REF42","doi-asserted-by":"crossref","unstructured":"Kitada S, Reed JC. MCL-1 promoter insertions dial-up aggressiveness of chronic leukemia. J Natl Cancer Inst.2004;96: 642-643.","DOI":"10.1093\/jnci\/djh153"},{"key":"2020021223391371900_REF43","doi-asserted-by":"crossref","unstructured":"Tangye SG, Raison RL. Human cytokines suppress apoptosis of leukaemic CD5+ B cells and preserve expression of bcl-2. Immunol Cell Biol.1997;75: 127-135.","DOI":"10.1038\/icb.1997.17"},{"key":"2020021223391371900_REF44","doi-asserted-by":"crossref","unstructured":"Chen F, Wang T, Wu YF, et al. Honokiol: a potent chemotherapy candidate for human colorectal carcinoma. World J Gastroenterol.2004;10: 3459-3463.","DOI":"10.3748\/wjg.v10.i23.3459"},{"key":"2020021223391371900_REF45","doi-asserted-by":"crossref","unstructured":"Tsai TH, Chou CJ, Cheng FC, Chen CF. Pharmacokinetics of honokiol after intravenous administration in rats assessed using high-performance liquid chromatography. J Chromatogr B Biomed Appl.1994;655: 41-45.","DOI":"10.1016\/0378-4347(94)00031-X"},{"key":"2020021223391371900_REF46","doi-asserted-by":"crossref","unstructured":"Egashira Y, Nagano H. A multicenter clinical trial of TJ-96 in patients with steroid-dependent bronchial asthma. A comparison of groups allocated by the envelope method. Ann N Y Acad Sci.1993;685: 580-583.","DOI":"10.1111\/j.1749-6632.1993.tb35921.x"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/2\/690\/1711731\/zh801405000690.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/2\/690\/1711731\/zh801405000690.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T04:39:28Z","timestamp":1581568768000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/2\/690\/21338\/The-natural-product-honokiol-induces"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,15]]},"references-count":46,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2005,7,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2004-11-4273","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,15]]}}}